TULIP trial: HER2-positive metastatic breast cancer PFS gain with trastuzumab duocarmazine

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site

Sep 19 / Springer Healthcare

TULIP trial: HER2-positive metastatic breast cancer PFS gain with trastuzumab duocarmazine

Oncology Breast Cancer ESMO-2021

Description

Barbara Pistilli reviews the positive findings for the phase 3 TULIP trial and the impact of new anti-HER2 antibody-drug conjugates in metastatic breast cancer

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.